Boehringer Ingelheim Pharmaceuticals and Eli Lilly's JARDIANCE and SYNJARDY proposed new indication to reduce CV risk
Read MoreJUN 28 EMDAC
Boehringer Ingelheim Pharmaceuticals and Eli Lilly's JARDIANCE and SYNJARDY proposed new indication to reduce CV risk
Read MoreMAY 25 EMDAC
Sanofi's insulin glargine and lixisenatide injection combination product and lixisenatide injection solo product for the treatment of adults with type 2 diabetes mellitus
Read MoreMAY 25 EMDAC
Sanofi's insulin glargine and lixisenatide injection combination product and lixisenatide injection solo product for the treatment of adults with type 2 diabetes mellitus
Read MoreMAY 24 EMDAC
Novo Nordisk''s NDA for insulin degludec and liraglutide injection for the treatment of adults with type 2 diabetes mellitus
Read MoreJUN 28 EMDAC
Boehringer Ingelheim Pharmaceuticals and Eli Lilly's JARDIANCE and SYNJARDY proposed new indication to reduce CV risk
Read MoreMAY 25 EMDAC
Sanofi's insulin glargine and lixisenatide injection combination product and lixisenatide injection solo product for the treatment of adults with type 2 diabetes mellitus
Read MoreMAY 24 EMDAC
Novo Nordisk''s NDA for insulin degludec and liraglutide injection for the treatment of adults with type 2 diabetes mellitus
Read MoreAPR 14 EMDAC
Discussion of the results from two cardiovascular outcomes trials for two DPP4 inhibitor's: AstraZeneca's saxagliptin and Takeda's alogliptin
Read MoreAPR 14 EMDAC
Discussion of the results from two cardiovascular outcomes trials for two DPP4 inhibitor's: AstraZeneca's saxagliptin and Takeda's alogliptin
Read MoreAPR 14 EMDAC
Discussion of the results from two cardiovascular outcomes trials for two DPP4 inhibitor's: AstraZeneca's saxagliptin and Takeda's alogliptin
Read More